KLA-Tencor (NASDAQ:KLAC)
Q4 2021 Earnings Call
Jul 29, 2021, 5:00 p.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Good afternoon. My name is Brittany, and I will be your conference operator today. At this time, I would like to welcome everyone to the KLA Corporation June quarter 2021 earnings conference call and webcast. [Operator instructions] I will now turn the call over to Kevin Kessel, vice president of investor relations.
Please go ahead.
Kevin Kessel — Vice President, Investor Relations
Thank you, and welcome to KLA’s fiscal Q4 2021 quarterly earnings call to discuss the results of the June quarter and the outlook for the September quarter. With me on today’s call is Rick Wallace, our chief executive officer; and Bren Higgins, our chief financial officer. During this call, we will discuss quarterly results for the period ended June 30, 2021, released this afternoon after market close. You can find the press release, shareholder letter, slide deck, and infographic on the KLA IR section of our website.
Today’s discussion is presented on a non-GAAP financial basis, unless otherwise specified. And whenever we make references to a year, we are referring to calendar years. A detailed reconciliation of GAAP to non-GAAP results is in the earnings materials posted on our website. Our IR website also contains future investor events as well as presentations, corporate governance information, and links to our SEC filings, including our most recent annual report and quarterly reports on Forms 10-K and 10-Q.
Our comments today are subject to risks and uncertainties reflected in the risk factor disclosure in our SEC filings. Any forward-looking statements, including those we make on the call today are subject to those risks, and KLA cannot guarantee those forward-looking statements will come true. Our actual results may differ significantly from those projected in our forward-looking statements. Let me now turn the call over to our chief executive officer, Rick Wallace.
Rick?
Rick Wallace — Chief Executive Officer
Hello, and thank you for joining us today. The June 2021 quarter showed continued momentum and strength for KLA. We delivered on our top- and bottom-line goals and progressed against our long-term strategic objectives. Specifically, quarterly revenue grew 7% sequentially and 32% year over year to $1.925 billion.
Non-GAAP earnings per share was $4.43, representing 15% sequential growth and 63% growth compared to the prior year. These results demonstrate strong growth momentum in our core markets, and the operating leverage in the KLA model. We continue to see increased customer demand across each of our major product groups. This demand is related to ongoing secular demand trends driving semiconductor industry growth across a broad range of markets and applications.
Our customers are increasing their strategic capex investments to address these growth markets and investing in their leading-edge R&D efforts. Against the strong demand backdrop, we are navigating evolving customer needs and persistent supply chain challenges. Still, KLA continues to outperform expectations by operating with purpose and precision and focusing on creating value for our customers, partners, and shareholders. This strong execution is led by our talented global teams continuing to go above and beyond, constantly rising to the challenge and opportunities of the marketplace.
I will quickly summarize our view of the industry demand environment. We’re in a great position relative to growth drivers that are creating momentum for the industry and our business. As a result, our outlook for the wafer fab equipment industry continues to move higher. We have increased our growth estimate from the low- to mid-20s stated last quarter to the low to mid-30s on a percentage basis.
This is from a base of approximately $61 billion in calendar 2020. With strong secular semiconductor demand trends continuing, we expect positive industry dynamics to sustain into calendar 2022. As our business benefits from this increased demand and our customers are also investing in leading-edge node development, fab optimization, and regional expansion, KLA offers the leading portfolio of products to solve our customers’ challenges. We continue to invest high levels of R&D to ensure we are constantly improving and remaining indispensable to our customers.
Specifically, we’re prioritizing investment in artificial intelligence and machine learning. KLA’s unique capabilities in leveraging these technologies and our product and service offerings help drive adoption and differentiates KLA against the competition. KLA benefits from long-standing market leadership and high levels of investment in advanced laser, sensor, optics, and data analytics technologies that leverage our AI and ML capabilities to identify critical defects in the production process and deliver ever-increasing precision in metrology applications. This investment helps our product and service offerings deliver best-in-class performance, lower process variability, higher yields, improved time to market, and reduced cost of ownership for our customers.
Our growing R&D investment is happening as process control intensity is increasing. KLA’s market leadership in the process control market remains greater than four times the nearest competitor as reported by Gartner Research in April of 2021. KLA’s sustained performance in process control is augmented by a broader position within the electronics ecosystem through our electronics, packaging, and components or EPC businesses and the contributions of our large and growing services business. For new and longtime KLA investors, it’s essential to point out that KLA’s market leadership is a result of consistent and focused execution of our company’s differentiated strategy.
With this favorable backdrop and our strong execution, we’re on track to achieve our 2023 financial targets well ahead of expectations. Let’s now move along to the top highlights for our most recent quarter. First, KLA continues to execute well and outperform expectations. In foundry and logic, we see simultaneous investments across multiple nodes, and our customers continue to increase demand forecasts.
We remain encouraged by the breadth and consistency of investment across our customer base. In memory, demand is strong and spread across a broader set of customers. During the quarter, we announced four new products targeting the automotive semiconductor market, including patterned and unpatterned wafer inspection and in-line test solutions. KLA’s automotive solutions aim to help customers identify and mitigate potential reliability defects in the development and manufacturing of automotive semiconductors early in the manufacturing process, improving device reliability and driving significant value for our customers.
Second, KLA’s strong market leadership and optical pattern wafer inspection has helped to drive strong relative growth for our semiconductor process control segment in 2021. In fact, optical pattern wafer inspection is forecast to be among the fastest-growing segments in WFE in 2021 for product segments over $1 billion in revenue and is poised to outpace the overall industry growth by a factor of two times this year. This follows similar growth and outperformance in 2020. Third, KLA’s flagship reticle inspection business is on pace for a record year in 2021, growing faster than the market and growing our leadership position.
As proof of that, we estimate that nearly all the reticles today at 5-nanometer are inspected by KLA systems. Our next-generation e-beam based 8XX mask inspection platform shipped last quarter and has begun customer qualification for applications at 3-nanometer and below. Fourth, our services revenue was $444 million in the June quarter or 23% of total sales. 75% of services revenue in our semiconductor process control segment and more than 90% of services revenue in our printed circuit board business is from recurring subscription-based contracts.
We believe these are among the highest subscription service rates in the industry. The services business is on track for another year of strong double-digit growth, well above our long-term growth model target. The growth is driven by our expanding installed base, higher utilization rates and increasing expansion of service opportunities at the trailing edge and the EPC group. Our semiconductor process control service business revenue continues to grow faster than the rate of the growth of the installed base, approximately 2.8 times faster from 2016 through 2020.
KLA Service business has the advantage of always working in close collaboration with our customers and partners, driving innovation and new initiatives for growth. Finally, in keeping with our commitment to deliver strong and predictable capital returns to our shareholders, today, we announced that KLA’s board of directors approved a 17% increase in the company’s quarterly dividend level from $0.90 to $1.05 per share. This is the 12th consecutive annual increase in our dividend level, which has grown at a compounded annual rate of 16% since inception in 2006. In addition, we announced a new $2 billion share repurchase authorization targeted for execution over the next 12 to 18 months.
We believe KLA’s track record of delivering strong capital returns is a key component of the KLA investment thesis and offers predictable and compelling value creation for our shareholders. Before moving into the financial highlights, let’s briefly summarize a few key points. KLA’s June quarter results demonstrate the critical nature of KLA’s products and services in enabling the digital transformation of our lives, the resiliency of the KLA operating model, and our commitment to productive capital allocation. KLA is exceptionally well-positioned with a comprehensive portfolio of products to meet demanding customer requirements that balance sensitivity and throughput.
The semiconductor and electronics landscape are constantly changing, and we are seeing broadening customer interest driven by more technology innovation than ever before at the leading edge. KLA also delivers enduring value through our commitment to corporate stewardship. We look forward to sharing an update on our ESG vision in our Global Impact report, which will be released in the coming weeks. And with that, I’ll pass the call over to Bren.
Bren Higgins — Chief Financial Officer
Thank you, Rick. KLA’s June quarter ’21 results highlight the soundness and strength of our ongoing strategies. We continue to demonstrate our ability to meet customer needs in a robust demand environment while expanding market leadership, growing operating profits, generating strong free cash flow, and maintaining our long-term strategy of productive capital allocation. Total revenue in the June quarter was $1.93 billion, toward the top end of the guided range.
Non-GAAP gross margin was 62%, at the midpoint of the guided range for the quarter of 61% to 63%. Non-GAAP EPS was $4.43, above the guided range of $3.47 to $4.35. GAAP EPS was $4.10. Non-GAAP total operating expenses were $419 million, about $7 million higher than expected, primarily due to engineering materials timing and adjustments to variable compensation programs.
Non-GAAP operating expenses included $241 million of R&D expense and $178 million of SG&A. At KLA, technical application support for our customers is included in SG&A and was $44 million in the quarter. The combination of R&D expense and technical applications represents about 70% of total operating expenses. KLA innovation is fundamental to our go-to-market strategy focused on differentiated solutions.
R&D is at the heart of KLA and remains a key element in driving our portfolio strategy and product differentiation. This in turn helps sustain our technology and market leadership. Non-GAAP operating income was very strong at 40.2%. Given higher revenue expectations for the second half of ’21, product development requirements, ongoing regionalization of additional customer engagement resources, and increased investment in our global infrastructure due to overall business volume, we expect non-GAAP operating expenses to be approximately $430 million in the September quarter.
Going forward, we will continue to size the company based on our target operating model, which delivers 40% to 50% incremental operating margin leverage on revenue growth over a multi-quarter horizon. Other income and expense in the June quarter net was $11 million, reflecting the gain on an investment in a strategic supplier that recently completed an initial public offering. This gain represented $0.15 of earnings per share at the company’s tax planning rate of 13.5%. You should continue to model other income and expense net at approximately $43 million per quarter.
The quarterly adjusted effective tax rate was 10.4%, reflecting the benefit of favorable audit adjustments recognized in the period. Non-GAAP net income was $684 million, GAAP net income was $633 million. Cash flow from operations was $466 million, and free cash flow was $410 million. The company had approximately 154 million diluted weighted average shares outstanding at quarter end.
Revenue for the semiconductor process control segment, including its associated service business, was $1.581 billion, a sequential quarterly increase of 5% and also up 37% compared with June of last year. The approximate semiconductor process control customer segment mix was in line with our forecast from April, as foundry/logic was 68% and memory was 32%. In memory, the business was split roughly 34% NAND and 66% DRAM. Revenue for electronics, packaging, and components group hit a record in the quarter, driven by continued strength in 5G mobile and infrastructure, as well as rising demand in automotive.
More specifically, the Specialty Semiconductor Process segment generated revenue of $98 million, up 7% sequentially and down 2% over the prior year. Demand in this segment was mostly driven by growth in the automotive power semiconductor applications, where we have a leading position in edge and deposition products. Specialty semiconductor processes’ performance was also highlighted by the second straight quarter of record bookings. PCB, display, and component inspection revenue was $247 million, up 20% sequentially and up 22% year over year with the data center driving strength in advanced PCB and packaging inspection.
KLA ended the quarter with $2.5 billion in total cash, total debt of almost $3.5 billion, and a flexible and attractive bond maturity profile supported by strong investment-grade ratings from all three agencies. We were also pleased to see Moody’s upgrade our debt rating in early June to A2 from BAA1, further underscoring the strength of our balance sheet and sustainability of our business and financial performance. We have tremendous confidence in our business over the long run and are committed to a long-term strategy of cash returns to shareholders, executing a balanced approach split between dividends and share repurchases, targeting long-term returns of at least 70% of free cash flow generated. Our announcement today of our 12th consecutive annual increase in the dividend and the additional share repurchase authorization are representative of our explicit approach and strong track record of predictable and productive capital deployment.
Over the last 12 months, KLA returned $1.5 billion to shareholders, including $559 million in dividends paid and $939 million in share repurchases. While circumstances can change, our current expectation remains that our capital returns for calendar ’21 will exceed 85% of expected free cash flow. KLA has a history of consistent free cash flow generation, high free cash flow conversion, and strong free cash flow margins across all phases of the business cycle and economic conditions. During the quarter, we generated $410 million in free cash flow and repurchased $300 million of common stock, while also paying $139 million in dividends.
Our overall semiconductor demand and WFE outlook continues to increase from our views earlier in the year. At the start of this year, we characterized the expected growth of the WFE market to be in the low teens, plus or minus a few percentage points. In April, we revised that view to the low to mid-20s on a percentage basis with a bias to the upside. Today, we see further improvement and expect the WFE market to grow in the low to mid-30s from approximately $61 billion in calendar in 2020 to approximately $81 billion at the midpoint in calendar ’21.
This reflects the broad-based strengthening of demand across all customer segments. KLA is in position to deliver strong relative growth this year, driven by our market leadership and strong momentum in the marketplace across multiple product platforms in both the semiconductor process control and EPC groups. Looking ahead, we remain encouraged by the sustainability of our current demand profile. As a result, we continue to expect total company revenue to improve sequentially quarter to quarter throughout the remainder of the calendar year.
We also expect the second half of calendar ’21 to grow in the mid-teens on a percentage basis versus the first half as more of our manufacturing capacity comes online to support this strong customer demand. Furthermore, our system shipment expectations point to meaningful growth in semiconductor process control equipment systems the second half of calendar ’21. This strong backdrop supports our current expectations of high 30s to low 40s year-over-year percentage growth for the semiconductor process control systems business in calendar ’21. As a result, we continue to believe that this business is positioned to outperform in ’21 relative to the overall WFE market.
Our September quarter guidance is as follows: total revenue is expected to be in a range of $2.02 billion, plus or minus $100 million. Foundry/logic is forecasted to be approximately 59% and memory is expected to be approximately 41% of Semiconductor Process Control Systems revenue to semiconductor customers. Within memory, DRAM is expected to be about 60% of the segment mix. We forecast non-GAAP gross margin to be in a range of 61.5% to 63.5%.
At the midpoint, this is 50 basis points above the June quarter level due principally to product mix. While in any given quarter, the mix of our business across products and business segments will affect our gross margin results, the structural trends, both in terms of product cost, manufacturing efficiency and product positioning remain compelling and are sustainable tailwinds going forward. Other model assumptions for September include non-GAAP operating expenses of approximately $430 million; other income and expense of approximately $43 million; and an effective adjusted tax rate of approximately 13.5%. Finally, GAAP diluted EPS is expected to be in a range of $3.76 to $4.64, and non-GAAP diluted EPS in a range of $4.01 to $4.89.
The EPS guidance is based on a fully diluted share count of approximately 153.5 million shares. In closing, the industry dynamics driving semiconductors and investments in WFE remain compelling, with broad-based customer demand and simultaneous investments across multiple technology nodes. We are encouraged by the leading indicators for our business, including our backlog and sales funnel visibility over the next couple of quarters. Our customers’ multiyear investment plans also point to the stability of demand in the future.
KLA continues to execute well and is on track to exceed our 2023 financial targets well ahead of expectations. The KLA operating model positions us well to outperform and guides our important strategic objectives. These objectives fuel our growth, operational excellence, and differentiation across an increasingly diverse product and service offering. They also underpin our sustained technology leadership, deep competitive mode, strong financial performance, and long-standing track record of free cash flow generation and capital return to shareholders.
And with that, I’ll now turn the call back over to Kevin to begin the Q&A.
Kevin Kessel — Vice President, Investor Relations
Thanks, Bren. Brittany, can you please queue up for questions.
Questions & Answers:
Operator
[Operator instructions] And we will take our first question from Harlan Sur with J.P. Morgan. Your line is now open.
Harlan Sur — J.P. Morgan — Analyst
Hi. Good afternoon, and great job on the quarterly execution and strong results. EUV adoption continues strongly. If I look at the outlook for EUV litho systems, that’s set to grow like mid-30% this year.
You have a positive exposure here via your wafer inspection systems, but also the strong leadership in EUV mask inspection and print check. I know this doesn’t represent your entire process control business, but it’s sort of a good proxy. But you guys are guiding your optical inspection, your mask inspection, and your overall process control business to grow well above that range. So what are the two or three dynamics that are driving the strength above EUV adoption? And more importantly, with the visibility that you guys have, how are you feeling about the sustainability of the overall second-half momentum into the first half of next calendar year?
Rick Wallace — Chief Executive Officer
Harlan, it’s Rick. Thanks for the question. You’re right. I think we are seeing a lot of strength in the process control portfolio, driven — as I mentioned in the prepared remarks, we look at optical wafer inspection and really seeing a lot of uptake on that.
What’s interesting about that is it’s a pretty good mix between GEN4 and GEN5. So both of the — GEN5 is more exposed, I would say, to the EUV dynamic, but we’re seeing more proliferation of GEN4 also as people continue to add advanced capability. And we expected that with the rising complexity really across the board, and it’s not just in the EUV areas of mainly logic and foundry, but also we’re seeing it in memory. That’s one area.
We mentioned also reticle is having a really strong year as the number of advanced designs continue. So we’re seeing both related to EUV, but also just increased process control intensity really across the entire portfolio. So that’s why we feel so strongly about the remainder of the year. And as Bren indicated, we’re looking into 2022 for that strength to continue.
Bren, do you want to provide more color?
Bren Higgins — Chief Financial Officer
Yes. So as Rick said, I think as we continue through the second half of this year, both those businesses are growing faster than market, as we said in the prepared remarks. In fact, I would think that the optical inspection business is one of the fastest-growing markets in all of WFE, if not the fastest. So there’s a lot of inflections around EUV, but also other process dynamics that are driving that.
But the introduction of EUV driving shrinks in the business — or shrinks in design rules is creating an opportunity for both platforms. And also leveraging optical inspection for validating reticle quality. Also at 5-nanometer in the reticle part of the business, you also have increasing reticle complexity. And our offering in that market, after a number of years where reticle complexity wasn’t changing all that much in the double patterning environment, as we move to EUV, radical complexity is changing dramatically.
And our offering is a more technical offering, and we’re getting strong customer interest in that product. So I think there’s sustainable tailwinds here through the rest of this year and as we move into ’22.
Harlan Sur — J.P. Morgan — Analyst
I appreciate that. And then on the gross margin front, can you just help us understand the uptick in your gross margins into the September quarter? It looks like component costs are rising. I’m assuming the team also has to pay expedite fees for some parts. And your end market mix is more weighted toward memory, which I would think would have some slight negative bias on gross margins.
So it’s great to see the team driving the margin profile higher, but just help us understand some of the drivers of that.
Bren Higgins — Chief Financial Officer
Well, customer mix doesn’t impact our margin profile. Our products across all segments have the same margin profile. So it really is a mix dynamic that is driving the quarter to quarter, the 50-basis-point increase. We have most of the growth quarter to quarter is coming from semi-process control systems.
And those carry higher margins than obviously our service business or our EPC business. So that’s been the bigger driver. We have supply chain challenges like everybody else, and we’re constantly trying to manage our way through those. Freight costs are higher.
Those are embedded. And maybe over time as some of those pressures alleviate, we’ll get a little bit of benefit from that into the future. But we certainly have that in our numbers and expecting it to remain at that level over the next couple of quarters. On the component side, there is pressure on components.
There’s pressure on raw materials for frames and steel specifically for the frames of our tools. So we’re dealing with that. Labor pressures are different around the world. We have factories at different locations, but we’re also dealing with that as well.
I would expect as we move forward, we’ll see some pressure. So far, it’s been offset by the strength of the volume. So we’ve worked with our suppliers and the volume upside has been favorable, but I do expect we’ll see some pressure on components. The way we price products tends to be value-centric.
We have a value pricing model. It’s not a cost-based model, but we’re certainly going to have to deal with that as it comes through. At these revenue levels into the future, I would think we’re probably looking at 10 to 20 basis points type of impact over time from some of the inflationary pressures on our COGS. But that’s contemplated in the guidance we provided in terms of our margin expectations moving forward.
Harlan Sur — J.P. Morgan — Analyst
OK. Great insights. Thank you.
Operator
And we will take our next question from John Pitzer with Credit Suisse. Your line is now open.
John Pitzer — Credit Suisse — Analyst
Yes. Thanks, Rick, Bren. Congratulations on the strong quarter. Thanks for letting me ask a question.
Rick, I wanted to go back to your prepared comments about the investments that you’re making in AI and ML. I mean, clearly, some of your peers have talked about big investments in that area. I’d be curious if you could help us understand how you think your approach might differ from theirs? How maybe your incumbency gives you an upper hand here? And as you think about this, is this a way to maintain already outstanding share? Or do you think there’s actually incremental revenue and SAM capability as you bring this out? And, Bren, maybe on the gross margin, what could be the influence to gross margin? I’m assuming this is mainly software or IP, which would seem to be gross margin accretive?
Rick Wallace — Chief Executive Officer
John, thanks for the question. We’ve been working on what has been, what is now called, AI and ML for years now. And of course, because we handle so much data, in our systems, especially in the optical wafer system but also in the reticle system, that we’ve been having to manage that data and look for signal in that data for a long time. What ML enables and machine learning enables along with AI is just extracting more information out of that data.
So as we continue to have more capability to manage it, our work on AI has proliferated across most of our products now in some form or another, but we continue to add upgrades. So I think to answer your question, 1 way to think about it is we can squeeze more capability out of existing generations by leveraging the algorithms and the AI work. And in the past, where we may have needed to ship wavelengths, for example, to get more capability, we can do that with algorithms. So 1 of the questions that had been brought up in the past was for example, the limitations of optical wafer inspection and why e-beam was going to maybe take a large part of the share.
That was the thesis a few years ago. But it was through AI and through ML and our advanced optics capability that we’ve actually created additional node capability out of the optical systems. So I think that’s another way that we’ve expanded and lengthened the lifetime of the products. Part of why GEN4 has a longer life now is we’re squeezing more capability out of that, leveraging it.
To answer your other question, it is expanding into our other products. Those were the first really in the work we do at reticle. But it’s also driving some opportunities for us in other segments as we expand the leverage of that capability into both metrologies, but also some of our traditionally lower-end wafer inspection systems that are applying in trailing edge capability. So it’s really kind of across the board.
And you’re right, it’s very — if you can amortize the engineering the way we do, it’s pretty accretive to the overall business volume because you’re — we do make a large investment. We’re by far the — we have the most investment going on of — no question, among our peers, because we’re doing it across such a broad portfolio. But we’re getting leverage as we have multiple products that are leveraging it. So Bren can speak to how that drives the P&L.
Bren Higgins — Chief Financial Officer
Yes, John. I think it’s much more of an operating margin statement or a reduction in R&D intensity is another way to think about it. Platform extendability is 1 of the biggest decisions we make in our product life cycle processes. We’re making choices, and we can extend platforms.
It means that over time, we get a higher return on investment on those engineering dollars. So we don’t have to go develop the next one, which is what drives significant cost in the model as you’re developing and bringing a new product to market. So by extending it, we see the leverage in our operating margins. Now in terms of gross margin, software content or software offerings are increasing across the whole company, not just within semi-process control, where we have businesses now that are starting to get to meaningful revenue levels where we’re selling software directly.
And we have that there and we also have it in the EPC business, where we’re providing simulation capabilities, data analytics, other computational methods, design-based capabilities to help point our inspectors and get more value out of the KLA offerings. So there’s a few dynamics that are there that I think are good for us in terms of solving some of these problems as technology road maps get more and more complicated, but then also driving operating margin leverage over time.
John Pitzer — Credit Suisse — Analyst
Thank you very much.
Bren Higgins — Chief Financial Officer
Thanks, John.
Operator
And we will take our next question from C.J. Muse with Evercore. Your line is now open.
C.J. Muse — Evercore ISI — Analyst
Yes. Good afternoon. Thank you for taking my question. As you think about your implied revenue guide for December, it looks like it’s about $250 million of process control.
And it sounds like that is coming on — based on new manufacturing capabilities that you’re bringing online. So curious, what’s the impact to gross margins at that time frame? And will that satisfy all pent-up demand, or will your lead times still be extended heading into calendar ’22?
Rick Wallace — Chief Executive Officer
Yes, C.J. It’s a great question. As far as lead times go, I think lead times are holding pretty flat. One of the challenges — and we had hoped that we’d start to see those pull in a bit, but demand has continued to increase.
So we’re seeing stronger demand, and we’re doing a lot of work to add capacity. So things aren’t extending out, but they’re not necessarily pulling in either. Yes. Based on our comments, you do have a ramp in our — in semi-process control equipment into the December quarter.
That’s a richer mix. So I’m not going to guide December, but that should carry a richer gross margin profile given the nature of the products that we’re shipping. That capacity has come online. I’ve got some revenue recognition dynamics related to new facilities and product transitions that’s pushing some of those shipments, if you will, that are happening this quarter — rather, that will happen next quarter.
So that’s also part of the higher sequential growth that we’re seeing into the December quarter. Did I answer your questions?
C.J. Muse — Evercore ISI — Analyst
Yes. That’s great. If I could just sneak a second one in. As you think about your foundry/logic outlook for 2022, and you talked about continued strength.
I was hoping you could speak to perhaps any changes that you see in the landscape, whether leading-edge, lagging-edge, EUV adoption, DRAM, anything we should be thinking about portfolio-wise that could be a little different than 2021?
Rick Wallace — Chief Executive Officer
Not really. I think just in terms of overall sustainability, we would expect to see the leading edge continue to invest as we go into next year. And given the public statements that have been made there, I think that’s pretty consistent with what we’re seeing. On the trailing edge side, we are seeing orders that are coming into backlog, but also in the funnel from a number of customers, a much more meaningful level of customers that haven’t invested all that much in the past and are addressing some of these automotive and industrial and some of these other more trailing edge challenges.
So I would think from a shipment or revenue point of view, we’ll see that business actually start to come to the P&L as we move into ’22. China has been mostly Logic-centric this year, native China. And so I think we’ll have to see how that plays out as we move into next year in terms of growth. Certainly, there’s, I think, sustainability with the business levels that have been elevating through this year.
But I would expect to see a little bit more memory activity probably next year in China. And I think that’s probably the 1 area where we don’t have as much visibility in terms of logic growth there. So I think those are the dynamics and how they’re playing. I think in terms of DRAM and NAND, I would expect those to continue to maintain the momentum that we’ve been seeing through ’21.
Bren Higgins — Chief Financial Officer
But C.J., I mean, just one thing to add, a lot of the business that we’re booking now is revenue in ’22. I mean, that’s part of our confidence in ’22. We’re filled out for ’21. And so that’s part of what we’re seeing.
And then some of the players you know who are trying to regain the lead, a lot of that investment hasn’t really shown up in our revenue numbers yet.
C.J. Muse — Evercore ISI — Analyst
Very helpful. Thank you.
Operator
And we will take our next question from Krish Sankar with Cowen and Company. Your line is now open.
Krish Sankar — Cowen and Company — Analyst
Yes. Hi. Thanks for taking my question, congrats on the strong results. I have two of them.
First one for reticle brand. I just want to ask the December quarter question in a different way. You said your semi-process control should grow 40% this year and half over half is mid-teens growth. So if I look at that, it looks like December quarter is around $2.3 billion, give or take.
Is that a decent proxy for December revenues? And are you not seeing any impact from any of the component shortages that’s affecting some of your friends in the industry? And then I had a follow-up.
Bren Higgins — Chief Financial Officer
Yes. So I’m not going to guide December specifically, what we try to do is give you some perspective on our expectations for growth of Semiconductor Process Control equipment for the year. That was the high 30s to low 40s statement. We also talked about the total company growing mid-teens half to half.
And so that was another statement there as well. So I don’t want to put a point out there in terms of the revenue guide, but hopefully, you can get there with the details we have provided. Components are a daily challenge. We are managing across our factories, across our teams, managing our suppliers to be able to deliver the parts that we need.
Some components have intrinsic lead times for us that are long-term. And so we have to make decisions, and we’ve been making decisions to make investments or for that to commit — make commitments to those suppliers to be able to provide that supply for us as we move into ’22. So it’s a challenge. We’re working our way through it.
I’m spending more time. I’ve been with KLA for 21 years, and I’m spending more time on supply chain than I ever have and certainly as CFO since 2013. So we’re dealing with it. We’re making our way through it.
And the guidance and context we provided contemplates what we expect to happen. It’s our best expectations based on what we know today.
Krish Sankar — Cowen and Company — Analyst
Got it. Got it. And then just as a follow-up, just one question on China. Obviously, you had really strong sales there in the June quarter.
And if I try to back out your ex-China sales it actually declined from March to June. And you also said China is mostly logic. So I’m kind of curious, are there that many logic/foundry players in China, or is this just a long tail of smaller players buying equipment? And any kind of color you can give on China with regards to your sales? And any kind of split between domestic and MNCs would be very helpful.
Bren Higgins — Chief Financial Officer
Yes. You have to remember that when we just talk about our mix of business, that’s the total company. So that includes EPC. So I believe our China percentage was like 32%.
If you look at the native investment as a percent of our Semiconductor Process Control segment, it’s about 25%. So the numbers, when you’re extrapolating like that can lead you to different conclusions. There are a number of small projects that are logic-centric projects in China that are targeting specific markets around IoT and image sensors and a bunch of those kinds of opportunities, obviously, automotive and industrial. So I think there are new projects in a lot of cases, which are going to be coming online over time.
But there is a lot of activity there. So yes, there are.
Krish Sankar — Cowen and Company — Analyst
Got it. Thank you very much.
Operator
And we will take our next question from Joseph Moore with Morgan Stanley. Your line is now open.
Joseph Moore — Morgan Stanley — Analyst
Great. Thank you. I wonder if you could talk about — you mentioned having new products for the automotive sector. And how are you thinking about this.
You sort of see the older foundry nodes looks like it’s going to be a source of sustainable strength for a while. Can you actually target that business a little bit more directly than you have? And just generally, what kind of activity are you seeing in the older foundry nodes?
Bren Higgins — Chief Financial Officer
Yes. Sure, Joseph. We’ve actually been engaged for quite a while with some of the leading automotive — even the automotive customers coming to us asking us to help them with their suppliers. That’s been going on for a few years.
What’s really happened now is it’s broadened the number of customers that are recognizing, and of course, the shortage of automotive semiconductors contributed to that. So we’ve been developing products that have, I would say, our adaptations of existing products that provide additional capability in support of automotive, where as you know, they’re looking for more reliability. There’s some cases where we’re helping traceability in terms of how they’re driving those fabs. So, yes, that’s an area we outlined in our 2019 Analyst Day where we talked about that was a growth area for us, and we believe it continues to be.
Obviously, it was a rough start in 2020, where a lot of customers shut down their plans for automotive semiconductor now to their dismay, but those are back on. And so we do have those products. We’re engaging with customers. There’s a strong demand for that, and we think that’s sustainable, and we think that will continue to grow as more of the automotive players see the value in that and that will just continue to broaden.
So we have a segment and a work area that we’re focused on that. And it’s also where our business that we got through Orbotech SPTS works also, some of the process capability there. So it’s more than just inspection. It’s broader for us than that.
So it’s pretty exciting. It’s a good growth area, and I think it’s one that we’ll continue to see progress over the next several quarters.
Joseph Moore — Morgan Stanley — Analyst
Great. Thanks very much.
Operator
And we will take our next question from Joe Quatrochi with Wells Fargo. Your line is now open.
Joe Quatrochi — Wells Fargo Securities — Analyst
Yes. Thanks for taking the question. Curious on your advanced packaging, you recently talked about packaging becoming more like front end. I was curious, how would you compare maybe contrast the two in terms of just the increasing capital intensity? And then maybe can you touch on your position in front end and how that maybe drives differentiation for the packaging?
Rick Wallace — Chief Executive Officer
I think there’s a couple of things. One is, as more of the big players are focused on packaging as a source of either maintaining differentiation or closing a differentiation gap, there’s more investment with larger players that know KLA. And frankly, I think we’re getting more seats at the table and engagements with them, because of their knowledge of KLA and their desire to put their bets behind a proven player. So we have capability.
We have some products. We’re doing some product development, some product adaptation, in support of that. But the technology there is moving. The process control intensity is significantly lower than it is, of course, in the leading edge.
But the rate of growth is very fast, the rate of growth in process control. So I would say we have an abundance of opportunities there to execute on, but it will require us to bring new capabilities. And so we’re engaging with our customers in that. And I can tell you, we’re getting as much pull there as we are in the front end for capabilities as customers try to accelerate their road map.
So we’re seeing strong growth as we increase the process control intensity. And it’s not just process control. Once again, some of the process equipment we have with SPTS is also being leveraged in that area as well as in our PCB business, which isn’t all inspection and measurement. So we do see strong growth.
We see a lot of potential consistent with the plans we laid out in 2019 at our Investor Day.
Bren Higgins — Chief Financial Officer
You also have the integration of the PCB board through IC substrate into the package. And so that’s a good driver for us moving forward. We’re working on new capability to better address that market. We also — the ICOS finished component inspection business is inspecting the finished packages.
And so that complexity is also driving an inflection in that market. We’re seeing very strong growth in that market as well. Probably the fastest-growing part of EPC is — today is through ICOS. So I think there’s a lot of opportunity, as Rick said.
And some of it’s dependent on us bringing new capability to market, but certainly, customers are trying to leverage the different positions we have across a number of different applications, trying to leverage the relationship with us to do more there.
Rick Wallace — Chief Executive Officer
Yes. And just to put a number on it. We said $400 million in 2019. We’re ahead of plan, and we can beat that, do more than that with some of the developments we’re contemplating.
So I think we’ve got the products now to perform to that, and we can do more, and we’re getting encouraged by the signs that we’re seeing as — engaging with these customers.
Joe Quatrochi — Wells Fargo Securities — Analyst
Super helpful. Thank you.
Operator
And we will take our next question from Patrick Ho with Stifel. Your line is now open.
Patrick Ho — Stifel Financial Corp. — Analyst
Thank you very much, and congrats on a nice quarter and outlook. Rick, maybe first off, a big picture and kind of the long-term outlook for the process control industry and your positioning. Gate all around is becoming — or it will be coming on board in the next few years. And I know you’ve probably been working with your customers.
You’ve got an incremental benefit when the industry transitions to FinFET transistors. How do you see the incremental opportunities as you go to gate all around where not only are you seeing new materials, but more materials in that transistor area?
Rick Wallace — Chief Executive Officer
Yes. It’s a great question. As you know, if you follow our business, any of these technology transitions, inflections, present opportunity for process control. Because the first thing that our customers need to figure out is how to get the process ramped.
So I think we’re seeing advanced indicators that that’s going to be great for adoption of additional capability. It’s also where the portfolio really matters. Because in the case of gate all around, adaptation to the GEN4 wafer inspection, in some ways, is more important than what GEN5 does. GEN5 is very important for the smaller defectivity that we need to detect and the lower rates, but GEN4 for the contrast.
And so some of the development we’ve been doing with our customers has been to tune our products for that advanced transistor capability. So I think that what you’ll see is a continued increase in process control intensity. The way we modeled it is relatively modest over the long term, but of course, the cumulative effect is it adds up. And that’s why we think process control intensity outgrows WFE on the order of 0.5 percentage point if we’re going from 15% to 15.5%, depending on what the aggregate, that’s a blended between Logic and Memory.
But we’ll see it over time that you’ll see it creep up as a result of those new inflections. Provided we have the products to support it, which is a lot of the work that we’ve been doing. So we feel like we’re in really good position to support our customers to do that.
Patrick Ho — Stifel Financial Corp. — Analyst
Great. That’s helpful. And my follow-up question, maybe for you, Bren. In terms of the investments you’re making, you talked about systems picking up, expanding capacity, bringing people on board to meet the increased shipments.
Services are also growing quite rapidly, and you’ve mentioned that it’s growing faster than the target CAGR you were looking at. What are the types of investments you need to make in services, given that not only is your semi services growing at the installed base growth, but PCB tends to be a very service-intensive business as well. And that marketplace is also showing signs of some more secular growth trends, given some of the marketplaces that they’re penetrating. How do you look at service investments both near term and over the next few years?
Bren Higgins — Chief Financial Officer
That’s a great question. And certainly trying to get more leverage out of the service businesses of the acquired companies, acquired businesses for KLA, has been one of our parts — a key component of the investment thesis when we look at these kinds of transactions. And smaller companies have a hard time trying to have the infrastructure just given the nature of their size to be able to support a broad service footprint. So being able to leverage our infrastructure, now the go to market is different.
How we engage with those customers is different. So leveraging the infrastructure we have is, I think, a big part of that. So there’s a big cost element. We made the investments I think we need to make.
Certainly, China and the investments we made back in 2016 and 2017 to build infrastructure to support the China business is great for us now, and we’re seeing scale on that. With some of the regionalization dynamics that are out there, if you see new fabs popping up, we have to build that capability in some new places. We think those are great opportunities for us because our customers rely on us to help bring those kinds of facilities up and to bring our capability to help them do that. And so whenever they’re building a new fab in a new geography, it creates a big opportunity for KLA.
We’re working on remote diagnostics, remote capabilities. So we can do a lot more diagnosis of tool problems from back here, from the factory or from our development teams, depending on what’s happening. One of the challenges in COVID, obviously, has been getting people in and out when we have an escalation situation. So I think those are the kinds of areas that we’re investing.
And it’s a great opportunity for us just in terms of growth, given the strength of the WFE, but also the lengthening of lifetime on the tools and how customers are using that from a utilization point of view.
Rick Wallace — Chief Executive Officer
Yes. And then the biggest investment really right now is in the workforce to support that. And so as Bren mentioned, we’re working on that. I think that hiring, training, onboarding as we anticipate the continued growth, is an area we’ve done well with.
But as you know, there’s a big demand for talent out there. So we have to keep on it, keep hiring and doing that training. So that’s probably the biggest area of investment over time is going to be the workforce.
Patrick Ho — Stifel Financial Corp. — Analyst
Great. Thank you.
Operator
And we will take our next question from Timothy Arcuri with UBS. Your line is now open.
Timothy Arcuri — UBS — Analyst
Hi. Thanks. I had two clarifications, Bren, and then I had a real question. The first two clarifications are, the comment you made about 15% half on half.
That was a corporate revenue comment. Somebody attached that to process control systems. But I don’t think — I think your process control systems comment was up like mid-30s, high 30s to 40% for the year. That half-on-half comment was a corporate revenue comment.
Correct?
Bren Higgins — Chief Financial Officer
That’s correct. Yes. And I attempted to clarify that in one of the earlier questions. But yes, you’re right.
That’s the total company aggregate revenue expectation second half versus first half, mid-teens.
Timothy Arcuri — UBS — Analyst
Perfect. And then the second clarification, did you say that domestic China is 25% of your process control systems revenue? Because WFE, it’s like 15% of total WFE.
Bren Higgins — Chief Financial Officer
Yes. In the quarter that we just completed.
Timothy Arcuri — UBS — Analyst
OK. OK. Got it. OK.
OK. OK. So for my real question, I guess. So I wanted to ask about actinic.
And it’s always really been tiered to high NA for EUV. Otherwise, you use the 8XX. And now you have the big microprocessor maker that’s now pushing more aggressively on High-NA. So are you going to accelerate your development time line for actinic?
Rick Wallace — Chief Executive Officer
Yes, Tim. It’s a great question. We feel confident that we will have the capability we need when it’s needed for the high NA. So I understand what your question is.
We believe that with the products that we have, with the 8XX in particular, and actually, the continued capability we’re seeing in 6XX, we feel that we will be there when the market is needed for the high NA.
Bren Higgins — Chief Financial Officer
And, Tim, just to also clarify on the China statement. So that’s of the semiconductor process control segment, which includes the service was 25% of the revenue in the June quarter.
Timothy Arcuri — UBS — Analyst
I see, including service. OK, Bren. Thank you so much.
Bren Higgins — Chief Financial Officer
Sure.
Operator
And we will take our next question from Vivek Arya with Bank of America. Your line is now open.
Vivek Arya — Bank of America Merrill Lynch — Analyst
Thanks for taking my question. I’m curious if, let’s say, hypothetically, WFE is $90 million or $100 billion next year, are you prepared to support that, right, from your capacity perspective? Or I guess a different way of asking the question is how much additional capacity are you planning to bring online next year?
Rick Wallace — Chief Executive Officer
Yes. Vivek, that’s an interesting question. And right now, what we’re trying to do is ramp up and to support the customer demand that we have and I have expectations for incremental capacity as we move forward. Now I feel like these are good investments to make for us over the long run, given our expectations for multi-year growth in WFE.
I think given the strength of the WFE investments and some of the end market drivers that we’re talking about that we would expect to see WFE grow over the next few years, at least in line with semiconductor revenue with rising capital intensity probably faster than that. So these investments and given the extendability of our platforms and the lifetime of our tools in terms of how we’re shipping to a very broad demand environment from a technology point of view, that these are investments that are important for us in terms of just being able to support that kind of environment moving forward, sort of a through-cycle over time statement. But we’re continuing to invest and make sure that we have the flexibility to be able to respond to our customer demand. So I think that’s — as I look at it right now in terms of the first half of the year in terms of expectations, hard for me to see how — it’s at least as strong as what we’ve seen in the second half of ’21 in terms of what we see in the funnel and our backlog in terms of how we’re managing it.
I don’t want to make any statements much beyond that.
Bren Higgins — Chief Financial Officer
I think the one thing I would add is we are cognizant of our customers’ desire to get more capabilities sooner. And we’re doing everything we can to size it. But the numbers you’ve talked about, we have contemplated in our plans.
Vivek Arya — Bank of America Merrill Lynch — Analyst
Maybe a quick follow-up, if I can. At what point do you sense that because of all the headlines around the capacity crunch, you have players who are now trying to become foundries on their own, that there is a pull-forward of demand. At what — what’s on your dashboard to tell you that whatever you’re shipping, right, that the utilization levels are quite high, and it’s not just customers scrambling to add more capacity. Like do you track what the usage is of the equipment that you ship?
Rick Wallace — Chief Executive Officer
Yes. Of course, we track the usage. I mean, that’s a metric that we’re looking at all the time. But I would back up a little bit and say that the industry actually has a self-governing mechanism in it, which is the ability of all the equipment companies to ramp to the demand.
And right now, when you talk to customers, they would take more shipments, I think, from everyone if they could get them sooner. So there’s a natural governance, and I’m sure you heard ASML talk about EUV through 2022. So it’s naturally governed by that. So I don’t — I think we’re — we’re in a good place for a sustained run at this point.
Kevin Kessel — Vice President, Investor Relations
Thanks, Vivek. Brittany, we have time, it looks like for one last question.
Operator
And we will take our final question from Sidney Ho with Deutsche Bank. Your line is now open.
Sidney Ho — Deutsche Bank — Analyst
Great. Thanks for taking my question. So speaking of these multi-year investment plans that you just talked about. There — obviously, there’s a lot of new fabs being announced in the past few months.
When do you expect those new fab investment to start generating revenue for you? And when do you expect to start seeing those orders coming in?
Rick Wallace — Chief Executive Officer
Well, in a lot of cases, we’ve already seen the orders. Right? So I think that customers are getting into the queue for deliveries. And then some products, deliveries could be 12 months from now. So it’s absolutely happening and customers are trying to make those commitments as they’re planning for their facilities.
Obviously, they plan across a lot of different types of equipment. And so those planning cycles tend to move around a little bit. Sometimes they’re also dependent on winning business and product ramps and so on. So there’s always a little bit of variability around the timing.
And then, of course, generally, as you’re trying to build something, there’s always infrastructure and delays and pull-ins that can happen associated with just construction overall. But yes, we’re absolutely seeing that demand in the backlog and certainly in the sales funnel.
Sidney Ho — Deutsche Bank — Analyst
OK. Great. Maybe my follow-up. It’s a lot of questions on the process — semi-process control side.
But on the EPC business, is 15% growth for this year still a realistic assumption given the strength in auto and 5G? And maybe you can talk about with or without the display side of things.
Rick Wallace — Chief Executive Officer
Yes. Including display, we’re in the high teens for that business. So we’re seeing strength there. Displays, about as we expected, and we’re seeing strength I mentioned earlier about component inspection.
Specialty semiconductor is also seeing strength. PCB is ahead of plan a little bit. So I think that’s moving along. Obviously, it’s very tied to mobility, 5G.
So, yes, we’re seeing that tick up in terms of expectations for growth out of that product group.
Operator
I would now like to turn the program back over to Kevin Kessler — Kessel, I apologize, for any additional or closing remarks.
Kevin Kessel — Vice President, Investor Relations
Thank you very much, and wanted to thank everybody for their time, their interest, and their questions. We will be in touch. Take care.
Operator
[Operator signoff]
Duration: 27 minutes
Call participants:
Kevin Kessel — Vice President, Investor Relations
Rick Wallace — Chief Executive Officer
Bren Higgins — Chief Financial Officer
Harlan Sur — J.P. Morgan — Analyst
John Pitzer — Credit Suisse — Analyst
C.J. Muse — Evercore ISI — Analyst
Krish Sankar — Cowen and Company — Analyst
Joseph Moore — Morgan Stanley — Analyst
Joe Quatrochi — Wells Fargo Securities — Analyst
Patrick Ho — Stifel Financial Corp. — Analyst
Timothy Arcuri — UBS — Analyst
Vivek Arya — Bank of America Merrill Lynch — Analyst
Sidney Ho — Deutsche Bank — Analyst
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.
You’re so awesome! I don’t believe I’ve truly read something like this before.
So great to find somebody with genuine thoughts on this
topic. Really.. thanks for starting this up. This website is one thing that
is required on the internet, someone with a bit of originality!
This output has been adapted and verified in rodent models 13; 14 priligy for sale However, the association of lower peak IgG levels with worse outcome suggests the possibility of a relation between serum IgG concentration and therapeutic effectiveness
purchase cialis online If patients were volume overloaded, nearly 80 became hypertensive when medications were withdrawn
Aw, this was a very good post. Taking a few minutes and actual effort to generate a great article… but what can I say… I put things off a whole lot and don’t
seem to get anything done.
propecia 1 mg Clomid is a synthetic chemical that induces ovulation by fooling your body into believing that there is less estrogen
Suggested Online site
viagra overdose Activated AhR on antigen presenting cells and naive CD4 T lymphocytes as well as increased levels of TGF 1 leads to suppression of the differentiation of Th17 and Th1 T cells as another immunosuppressive aspect 149
over the counter viagra Over the past decades, extensive knowledge has been gained regarding mechanisms of ERО± in transcriptional regulation of downstream target genes
A further issue is that video games are generally serious in nature with the most important focus on mastering rather than entertainment. Although, there’s an entertainment aspect to keep children engaged, each one game is frequently designed to work towards a specific skill set or program, such as math or research. Thanks for your article.
order tadalafil 5mg sale cialis 40mg price buy ed pills generic
purchase absorica generic purchase accutane pills azithromycin 250mg for sale
azipro pill buy neurontin no prescription buy generic neurontin over the counter
cost furosemide ventolin 4mg uk ventolin 2mg cheap
vardenafil 10mg drug buy generic plaquenil hydroxychloroquine 400mg brand
altace order online oral amaryl 4mg how to get etoricoxib without a prescription
vardenafil 20mg cheap tizanidine us hydroxychloroquine 400mg canada
order mesalamine 800mg for sale buy irbesartan 300mg generic buy generic avapro
benicar us oral verapamil buy divalproex for sale
generic temovate buy amiodarone cheap buy generic cordarone
acetazolamide online buy isosorbide without prescription imuran 50mg pills
coreg 25mg cost buy generic chloroquine aralen pill
lanoxin 250 mg us purchase lanoxin for sale oral molnunat 200 mg
brand naproxen 250mg omnicef online lansoprazole for sale online
proventil order online purchase proventil pills purchase pyridium generic
order montelukast 5mg sale generic montelukast 10mg buy avlosulfon generic
order generic olumiant 2mg glycomet without prescription buy generic lipitor 10mg
adalat 30mg pill order aceon 4mg fexofenadine ca
oral norvasc prilosec over the counter buy omeprazole cheap
dapoxetine tablet cytotec sale brand orlistat 60mg
metoprolol 100mg without prescription tenormin 100mg over the counter buy medrol cheap
buy diltiazem without prescription allopurinol 300mg over the counter zyloprim 100mg uk
aristocort 4mg oral order triamcinolone 10mg generic buy loratadine 10mg online cheap
order crestor sale order zetia generic motilium 10mg uk
ampicillin ca buy generic flagyl 200mg cheap metronidazole 400mg
tetracycline 250mg us order sumycin 250mg sale order baclofen 25mg without prescription
order toradol 10mg pill propranolol canada buy inderal pills
bactrim usa keflex 250mg tablet cleocin online
buy cheap generic clopidogrel buy generic warfarin coumadin tablet
buy erythromycin 500mg online buy sildenafil 50mg without prescription tamoxifen without prescription
order metoclopramide 20mg sale order losartan 50mg without prescription buy esomeprazole cheap
rhinocort drug cefuroxime over the counter buy careprost eye drops
order topamax for sale purchase levofloxacin pills order levofloxacin
methocarbamol 500mg brand oral sildenafil 50mg order sildenafil 100mg generic
purchase avodart pills cost zantac 300mg order mobic 7.5mg
order aurogra generic purchase estrace buy estradiol 2mg for sale
how to get celebrex without a prescription order tamsulosin pills buy ondansetron pills
lamotrigine oral buy generic prazosin 2mg minipress generic
aldactone 100mg for sale valtrex 1000mg brand valacyclovir 1000mg cost
finasteride order online viagra 100mg order sildenafil pill
order tretinoin gel generic purchase tadalis pills order avana 200mg generic
buy tadalafil tablets buy cialis 5mg pill cost sildenafil 50mg
buy generic tadacip for sale generic indomethacin indomethacin 75mg brand
order tadalafil 5mg sale diflucan online order buy ed pills online usa
order terbinafine 250mg sale trimox 250mg us buy trimox for sale
buy sulfasalazine 500mg for sale order sulfasalazine 500mg generic verapamil for sale
order anastrozole sale order generic clonidine buy catapres
order divalproex pill imdur 40mg tablet isosorbide 40mg pill
azathioprine 25mg cheap order digoxin where to buy telmisartan without a prescription
buy molnunat 200mg pill order molnunat 200 mg for sale cefdinir sale
top ed pills viagra medication viagra 50mg brand
buy lansoprazole pills for sale pantoprazole 40mg brand order protonix 40mg sale
cheap phenazopyridine 200mg buy generic singulair 5mg cost amantadine 100 mg
buy avlosulfon generic buy generic avlosulfon over the counter aceon sale
buy ed pills without a prescription tadalafil order online cialis 40mg brand
fexofenadine over the counter ramipril ca amaryl 1mg usa
purchase etoricoxib without prescription astelin cheap azelastine 10 ml oral
order terazosin 5mg sale buy terazosin no prescription generic cialis 10mg
purchase avapro online buspar 5mg usa order buspar 10mg pill
amiodarone 200mg tablet how to get carvedilol without a prescription buy phenytoin no prescription
buy albenza online buy albendazole 400mg generic order provera 5mg generic
oral oxybutynin 5mg buy oxybutynin 2.5mg online cheap order alendronate pills
order biltricide 600 mg online cheap buy praziquantel 600mg sale order generic periactin 4 mg
buy generic macrodantin over the counter buy furadantin 100 mg without prescription nortriptyline 25mg over the counter
buy fluvoxamine 100mg without prescription purchase cymbalta pills order cymbalta 20mg online
glucotrol medication buy glipizide pill cheap betnovate
acetaminophen pills order paracetamol 500mg without prescription order famotidine sale
anafranil 50mg for sale progesterone brand where to buy prometrium without a prescription
cheap tacrolimus 1mg remeron 15mg brand order ropinirole 2mg online
order tinidazole 500mg sale buy olanzapine 10mg for sale nebivolol tablet
diovan cheap diovan 160mg usa combivent cost
rocaltrol price buy tricor without prescription buy tricor 160mg generic
order decadron 0,5 mg generic dexamethasone 0,5 mg us buy nateglinide for sale
oxcarbazepine 600mg usa alfuzosin brand order ursodiol 300mg without prescription
capoten 120mg drug generic candesartan 8mg buy tegretol generic
order bupropion 150 mg online cheap order strattera generic strattera 10mg canada
order ciprofloxacin 500 mg sale buy lincocin without a prescription cefadroxil 500mg over the counter
order quetiapine 50mg generic order escitalopram online escitalopram 20mg for sale
buy generic combivir buy zidovudine no prescription accupril for sale online
purchase frumil generic order frumil acivir without prescription
bisoprolol 5mg tablet order oxytetracycline order terramycin 250mg for sale
buy valcivir generic famvir 250mg pill floxin 400mg pills
cefpodoxime sale order vantin 200mg pills flixotide cheap
order generic levetiracetam 500mg viagra 100mg tablet viagra 100mg over the counter
order tadalafil 5mg without prescription buy viagra 100mg pill usa viagra overnight
order zaditor generic order ketotifen 1mg without prescription order imipramine 25mg online
minoxytop solution cheap ed pills best ed pills non prescription
buy precose paypal purchase repaglinide online cheap buy generic griseofulvin over the counter
aspirin 75mg without prescription buy levofloxacin 500mg generic purchase imiquimod online cheap
dipyridamole 100mg canada buy generic pravachol pravachol 10mg cheap
buy melatonin 3 mg online cheap meloset usa danocrine uk
buy cheap generic duphaston forxiga 10 mg pill buy empagliflozin 25mg for sale
buy florinef 100 mcg online cheap order generic imodium 2mg purchase imodium sale
monograph 600 mg usa buy cilostazol 100mg online pletal 100mg brand
buy prasugrel pills for sale dramamine 50mg sale detrol 2mg pill
buy generic ferrous 100mg ferrous sulfate generic order sotalol pills
pyridostigmine 60 mg usa feldene usa maxalt 10mg us
enalapril cheap buy generic duphalac over the counter lactulose drug
zovirax generic buy zovirax eye drop for sale buy exelon generic
premarin buy online viagra overnight delivery cheap viagra pill
buy omeprazole 10mg online order generic singulair 5mg metoprolol pills
order micardis 20mg online telmisartan order online buy generic movfor
cheap tadalafil 5mg tadalafil 20mg sale buy viagra 50mg for sale
cenforce 50mg brand naprosyn 500mg us aralen usa
buy modafinil 100mg generic buy prednisone 40mg buy deltasone pills
cefdinir sale buy generic glucophage for sale buy lansoprazole 30mg online
accutane order online buy isotretinoin 10mg online order azithromycin pills
oral azithromycin buy generic azipro how to get neurontin without a prescription
atorvastatin 40mg brand brand amlodipine 10mg amlodipine 5mg pills
real money games online blackjack for real money usa buy lasix 100mg generic
buy protonix no prescription buy pantoprazole 20mg for sale pyridium pill
free spins no deposit casino best online casinos that payout order albuterol 2mg
poker games online real poker online ivermectin 50 mg
buy symmetrel 100mg sale cheap symmetrel avlosulfon 100mg over the counter
empire casino online order levothyroxine pill purchase synthroid generic
clomiphene 100mg ca cost isosorbide azathioprine cost
medrol 8mg tablet order nifedipine online order triamcinolone 10mg without prescription
buy generic coversyl aceon uk buy generic allegra
oral dilantin buy ditropan for sale ditropan 5mg usa
order lioresal generic toradol for sale buy toradol 10mg online
where can i buy claritin order claritin without prescription dapoxetine 30mg ca
where can i buy lioresal buy ozobax paypal order toradol pills
fosamax uk buy furadantin 100 mg online cheap oral furadantin
propranolol us purchase plavix without prescription plavix online
order nortriptyline generic buy methotrexate for sale buy acetaminophen 500 mg pills
glimepiride over the counter etoricoxib ca order etoricoxib 120mg sale
buy coumadin online cheap buy paroxetine 20mg generic buy metoclopramide without prescription
orlistat 60mg pills oral diltiazem purchase diltiazem generic
buy pepcid 40mg for sale buy cozaar 25mg pills purchase prograf online
cost astelin zovirax 800mg drug buy generic irbesartan for sale
esomeprazole 20mg cost buy nexium online topamax order
sumatriptan price order levaquin 250mg generic dutasteride medication
buy zyloprim sale buy temovate medication buy rosuvastatin 20mg online cheap
zantac 300mg cost zantac 150mg brand buy celecoxib generic
buspin order buy cordarone 100mg sale order amiodarone 200mg without prescription
buy motilium order carvedilol generic tetracycline 500mg ca
purchase flomax without prescription tamsulosin over the counter buy generic zocor
spironolactone 100mg brand buy generic propecia online cheap propecia 5mg
help with writing a research paper academic writers online pay to do assignment
fluconazole 100mg without prescription cipro 500mg uk baycip brand
purchase aurogra generic order estrace 1mg online cheap order estradiol for sale
how to buy metronidazole metronidazole cheap buy cephalexin generic
lamictal 50mg tablet order prazosin 1mg online order vermox 100mg online cheap
buy cleocin online erectile dysfunction pills over the counter order sildenafil 50mg pills
tretinoin gel for sale brand tretinoin cream purchase avana for sale
buy tamoxifen 20mg pill how to buy symbicort budesonide order
order generic tadalafil tadacip 20mg drug purchase indomethacin generic
order ceftin 250mg generic methocarbamol for sale order methocarbamol online
desyrel 100mg for sale purchase suhagra pills buy clindac a gel for sale
terbinafine 250mg brand order terbinafine 250mg without prescription free roulette games
aspirin 75 mg usa purchase aspirin sale real money online casino
write papers online cefixime 100mg for sale buy suprax generic
help me with my research paper all free slots play now online roulette for real money
buy cheap trimox trimox 500mg usa biaxin for sale
calcitriol 0.25 mg pill buy generic tricor order tricor pills
order catapres 0.1 mg without prescription order generic spiriva 9mcg buy spiriva 9mcg without prescription
strong acne medication from dermatologist buy generic oxcarbazepine for sale trileptal 300mg cheap
purchase minomycin online cheap order requip generic order requip 1mg generic
purchase alfuzosin list of antinausea drugs drugs that reduce stomach acid
letrozole medication femara online buy cost aripiprazole 30mg
natural supplements for quitting smoking buy strong painkillers online brand of pain reliever
medroxyprogesterone 5mg cheap purchase medroxyprogesterone for sale buy hydrochlorothiazide sale
any treatment for facial herpes daily antiviral medication for herpes is ozempic fda approved for prediabetes
buy duloxetine pills provigil 100mg ca modafinil 200mg usa
otc medication for stomach ulcer what are vasodilators used for order antibiotics for uti online
online birth control prescription canada ejaculation treatment pills best supplements for men over 50
order deltasone 20mg generic buy deltasone 10mg generic buy amoxicillin 1000mg generic
safest antacid to take non prescription medication for nausea abdominal gas treatment
azithromycin 250mg pills gabapentin 800mg cost buy neurontin 600mg pill
buy actigall pill bupropion medication order zyrtec 10mg without prescription
order strattera 25mg for sale sertraline 100mg canada purchase zoloft pill
generic lasix 100mg buy asthma pills onlin get asthma pills online
buy escitalopram revia 50mg cost cost revia 50mg
augmentin online order clomiphene order clomid 100mg online cheap
purchase ipratropium decadron 0,5 mg uk oral zyvox 600mg
nateglinide price cost atacand 16mg atacand 16mg tablet
vardenafil uk buy generic plaquenil hydroxychloroquine 400mg oral
order tegretol for sale cost lincocin buy lincocin for sale
order cenforce 50mg without prescription buy generic aralen buy metformin 1000mg without prescription
brand duricef 250mg order cefadroxil online cheap buy epivir online
lipitor 40mg usa atorvastatin price buy lisinopril 2.5mg
dostinex 0.5mg ca priligy over the counter dapoxetine 90mg brand
methylprednisolone 8mg pills where to buy desloratadine without a prescription desloratadine oral
cytotec online order purchase diltiazem pills how to buy diltiazem
cost nootropil clomipramine 25mg sale order anafranil 25mg pills
Viagra * Cialis * Levitra
All the products you are looking seeking are currently close by for the duration of 1+1.
4 more tablets of one of the following services: Viagra * Cialis * Levitra
https://pxman.net
Viagra * Cialis * Levitra
All the products you are looking for are currently convenient as far as something 1+1.
4 more tablets of identical of the following services: Viagra * Cialis * Levitra
https://pxman.net
Viagra * Cialis * Levitra
All the products you are looking seeking are currently available as far as something 1+1.
4 more tablets of one of the following services: Viagra * Cialis * Levitra
https://xn--2i0bm4p0sf2wh7vdmsy.net